PrEP, or pre-exposure prophylaxis, was first approved by the FDA in 2012 to prevent people exposed to HIV from becoming ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

The trial pitted PrEP lenacapavir against standard-of-care once-daily Truvada (emtricitabine + tenofovir disoproxil fumarate). New safety data from the trial indicated that lenacapavir was ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

While the daily PrEP pills Truvada and Descovy (both from Gilead) are around 99% effective when taken consistently, additional options are still needed. Some people have trouble remembering to take a ...

Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.

Two large studies were conducted to see if Apretude is safe and effective as a PrEP regimen in people at risk of getting HIV. In both studies, Apretude was compared to Truvada, an HIV PrEP ...

Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...

It still has a long way to go to challenge Gilead’s PrEP franchise, however, which has raked in billions of dollars since Truvada first reached the market for PrEP in 2012. It is thought that ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 ...